Abstract
Cholesterol 25-hydroxylase (CH25H) is an interferon (IFN)-stimulated gene that shows broad antiviral activities against a wide range of enveloped viruses. Here, using an IFN-stimulated gene screen against vesicular stomatitis virus (VSV)-SARS-CoV and VSV-SARS-CoV-2 chimeric viruses, we identified CH25H and its enzymatic product 25-hydroxycholesterol (25HC) as potent inhibitors of SARS-CoV-2 replication. Internalized 25HC accumulates in the late endosomes and potentially restricts SARS-CoV-2 spike protein catalyzed membrane fusion via blockade of cholesterol export. Our results highlight one of the possible antiviral mechanisms of 25HC and provide the molecular basis for its therapeutic development.
Keywords:
COVID-19; SARS-CoV-2; innate immunity; interferon; virus entry.
Copyright © 2020 the Author(s). Published by PNAS.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antiviral Agents / pharmacology
-
COVID-19 / metabolism
-
COVID-19 / pathology
-
COVID-19 / virology
-
COVID-19 Drug Treatment*
-
Endosomes / genetics*
-
Endosomes / metabolism
-
Humans
-
Hydroxycholesterols / pharmacology*
-
Interferons / metabolism
-
Membrane Fusion / drug effects
-
SARS-CoV-2 / drug effects
-
SARS-CoV-2 / metabolism
-
SARS-CoV-2 / pathogenicity
-
Severe acute respiratory syndrome-related coronavirus / drug effects
-
Severe acute respiratory syndrome-related coronavirus / metabolism
-
Severe acute respiratory syndrome-related coronavirus / pathogenicity
-
Spike Glycoprotein, Coronavirus / antagonists & inhibitors*
-
Spike Glycoprotein, Coronavirus / genetics
-
Virus Internalization / drug effects
-
Virus Replication / drug effects
Substances
-
Antiviral Agents
-
Hydroxycholesterols
-
Spike Glycoprotein, Coronavirus
-
spike protein, SARS-CoV-2
-
25-hydroxycholesterol
-
Interferons